drugset / Trial / NCT00491543

Evaluation of ALT-2074 in Subjects With Type-2 Diabetes, Haptoglobin Type 2-2 Genotype and Coronary Artery Disease

NCT00491543 ↗

Phase 2 Completed 66 enrolled Synvista Therapeutics, Inc
RandomizedParallel-groupDouble-blindTreatment

Summary

ALT-2074 (BXT-51072) belongs to a class of drugs called "glutathione peroxidase mimics." ALT-2074 works by imitating a substance produced in various tissues in the body, which prevents damage of the heart and blood vessels. Diabetic patients with a haptoglobin 2-2 genotype have poor cardiovascular clinical outcomes. The purpose of this study is to assess the safety, the pharmacokinetic profile and characterize the effect on biomarkers of inflammation and oxidative stress of repeat doses of ALT 2074. Subjects must be diabetic, with evidence of coronary artery disease and a haptoglobin 2-2 genotype

Timeline

Start
2007-06
Primary completion
—
Completion
2008-05

Drugs

EvaluationDrugModalityDoseRoute
Subject ALT-2074 Small molecule 20 mg —
Subject ALT-2074 Small molecule 40 mg —
Subject ALT-2074 Small molecule 80 mg —